What Has Been the Growth Trajectory for the Antisense & RNAi Therapeutics Market in Recent Years?
The antisense & rnai therapeutics market has seen considerable growth due to a variety of factors.
• The market for antisense and RNAi therapeutics has witnessed a quick expansion in the past few years. There is an expected increase from $1.75 billion in 2024 to $1.94 billion in 2025, marking a compound annual growth rate (CAGR) of 11.2%.
The historical period's growth is rooted in factors such as increased funding, technological advances, and higher healthcare spending. Additionally, a rapidly aging population and economic growth in emerging markets have also played a significant role.
What Can Be Expected from the Antisense & RNAi Therapeutics Market in the Coming Years?
The antisense & rnai therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for antisense and RNAi therapeutics is projected to experience swift expansion in the imminent years. The market value is anticipated to ascend to $3.18 billion in 2029, with a compound annual growth rate (CAGR) of 13.1%.
Strides in healthcare accessibility, an escalating incidence of cancer, and the boosted demand for antisense and RNAi therapeutics due to COVID-19 can account for the predicted growth during the forecast period. Upcoming trends for the prospective period comprise coordinated efforts in researching and developing RNA therapeutics for rare diseases, application of nanoparticles, advancement of innovative and enhanced antisense and RNAi therapeutics, and partnering with other firms to innovate products and boost earnings.
What Are The Key Drivers Fueling Growth In The Antisense & RNAi Therapeutics Market?
The increasing incidence of heart artery diseases, neurodegenerative diseases, and infectious diseases is anticipated to bolster the demand in the antisense & RNAi therapeutics market. Treatment methodologies including RNA interference and antisense oligonucleotides, which manipulate gene expression, are utilized to treat various neurodegenerative disorders through the repair of mutant genes. For example, a report by the American Heart Association published in January 2024 indicated that the age-adjusted rate of death from cardiovascular diseases has risen to 233.3 per 100,000, indicating a 4.0% increase from the previous year. Therefore, the surging incidence of a variety of neurodegenerative and infectious diseases is projected to fuel the expansion of the antisense & RNAi therapeutics market.
How Is the Antisense & RNAi Therapeutics Market segmented?
The antisense & RNAi therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
Pre-Book The Antisense & RNAi Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Antisense & RNAi Therapeutics Market?
To survive in the fiercely competitive antisense & RNAi therapeutics market, major corporations are implementing strategic actions such as collaborations and partnerships. This business strategy sees two or more firms joining forces to accomplish a shared aim or objective. For example, Orbit Discovery Limited, a US-based service provider for peptide discovery, aligned with UK-based SanegeneBio Inc., which specializes in the development of innovative RNAi-based medicines, in January 2023. They joined forces to identify tissue-specific delivery of RNA medicine for efficient gene knockdown and develop a series of progressive RNAi therapeutics. The partnership includes the identification of successful hits and internalization studies based on cells, with Sanegene given the opportunity to further progress the hits derived from these screening endeavors, utilizing Orbit's exclusive technology for fast peptide lead discovery. Orbit Discovery's exceptional peptide display engine permits the screening of extensive peptide libraries, thus providing quicker discovery periods for pertinent peptide leads hinged on affinity and functional screens.
Who Are the Key Players in the Antisense & RNAi Therapeutics Market?
Major companies operating in the antisense & RNAi therapeutics market include:
• Biogen Inc.
• Ionis Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Moderna Inc.
• Sanofi S.A.
• Dicerna Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Acuitas Therapeutics
• Adhera Therapeutics Inc.
• EdiGene Inc.
• Sirnaomics Inc.
• Suzhou Ribo Life Science Co. Ltd
• Biocon Limited
• Quark Pharmaceuticals
• GlaxoSmithKline Plc
• Shanghai Junshi Biosciences Co. Ltd.
• AstraZeneca
• Benitec Biopharma Limited
• Silence Therapeutics
• Dynacure
• CN Bio Innovations
• Sarepta Therapeutics
• Mallinckrodt
• Regeneron Pharmaceuticals Inc.
• Alcyone Lifesciences Inc.
• Bio-Path Holdings Inc
• Calando Pharmaceuticals
• Enzon Pharmaceuticals Inc
• Celnova Pharma
• Pfizer Inc.
• Taiba Pharma
• Gen Ilaç ve Saglik Ürünleri A.S.
• Egypt Otsuka Pharmaceutical
What Is The Most Dominant Region In The Antisense & RNAi Therapeutics Market?
North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
